Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26954668
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Nephron
2016 ; 134
(1
): 37-42
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Targeting Glycosphingolipid Metabolism to Treat Kidney Disease
#MMPMID26954668
Shayman JA
Nephron
2016[]; 134
(1
): 37-42
PMID26954668
show ga
The enhanced expression of glucosylceramide-based glycosphingolipids (GSLs) is a
hallmark of many forms of renal disease including diabetic nephropathy,
polycystic kidney disease and renal cell carcinoma. A common feature of each of
these renal disorders is the preference metabolism via aerobic glycolysis. While
aerobic glycolysis is an inefficient way to generate ATP, aerobic glycolysis
promotes the formation of substrates important for the production of biomass,
including lipids, amino acids and nucleotides, through the pentose phosphate
pathway. Two products that are essential for the synthesis of glucosylceramide
and more complex GSLs are generated through the pentose phosphate pathway. These
products are reducing equivalents in the form of NADPH and UDP-glucose. In
experimental models of each of these disorders, inhibition of glucosylceramide
synthase with eliglustat or related analogues reverses the disease phenotype
suggesting that blocking GSL synthesis should be explored as a potential
treatment strategy.